Drugs · acquisition-cost intelligence
IMITREX
sumatriptan· ingredient sumatriptan· SUMATRIPTAN SUCCINATE 4 mg/.5mL; SUMATRIPTAN SUCCINATE 6 mg/.5mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$461.02
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other sumatriptan products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Sumatriptan | $0.34058 | −$460.68 |
| Treximet | $11.67 | −$449.35 |
| Sumatriptan | $15.06 | −$445.96 |
| sumatriptan | $16.06 | −$444.96 |
| sumatriptan | $17.57 | −$443.45 |
| sumatriptan | $69.54 | −$391.48 |
| IMITREX | $72.50 | −$388.53 |
| Tosymra | $108.15 | −$352.87 |
Medicare Part D coverage · CY2026
On 1 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 100% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.